Funds managed by BlackRock added $40m to the $60m supplied for the drug development technology developer by investors including Novo, Evotec and Bristol Myers Squibb in May.
UK-based drug discovery technology developer Exscientia increased a series C round featuring corporates Novo, Evotec and Bristol Myers Squibb to $100m yesterday following a $40m extension from funds managed by BlackRock.
Novo led the round’s $60m first tranche in May 2020, investing alongside fellow pharmaceutical firm Bristol Myers Squibb, drug discovery and development services firm Evotec and private equity firm GT Healthcare Capital, through unnamed limited partners.
Exscientia exploits artificial intelligence technology to precisely engineer drug candidates rather than…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
